安大略省老年糖尿病患者潜在过度治疗与不良事件风险:一项基于人群的研究
该研究基于加拿大安大略省行政数据,纳入108,620例≥75岁、2014-2015年接受至少一种降糖药物治疗的社区居住老年糖尿病患者。结果显示61%的患者达到强化血糖控制(HbA1c<53 mmol/mol[<7%]),21.6%使用高风险药物(胰岛素、磺脲类)达到强化控制;经倾向评分逆概率加权后,高风险药物强化控制较保守控制(HbA1c 54-69 mmol/mol[7.1-8.5%])且低风险药物者的复合结局(急诊、住院或死亡)风险增加近50%(RR 1.49,95%CI 1.08-2.05)。
要点
- ≥75岁糖尿病患者中61%被治疗至HbA1c<7%的强化控制水平。
- 21.6%的老年患者使用胰岛素或磺脲类达到强化控制。
- 高风险药物强化控制与30天内急诊、住院或死亡复合风险增加相关(RR 1.49)。
核心结论
- 老年糖尿病患者中强化血糖控制普遍存在,使用高风险药物达到强化控制与不良事件风险增加相关。
- 研究提示需要重新评估老年患者的血糖目标及可能导致低血糖的降糖药物使用。
研究设计与样本
- 回顾性、基于人群的队列研究,使用安大略省行政数据。
- 纳入≥75岁、2014-2015年接受至少一种降糖药物治疗的社区居住老年糖尿病患者108,620例。
- 按HbA1c水平分为强化控制(<53 mmol/mol[<7%])或保守控制(54-69 mmol/mol[7.1-8.5%]),并按药物风险分为高风险(胰岛素、磺脲类)或低风险(其他)。
- 采用倾向评分逆概率加权比较高风险药物强化控制与低风险药物保守控制的复合结局(30天内急诊、住院或死亡)。
主要发现
- 队列平均年龄80.6±4.5岁,女性占49.7%,平均糖尿病病程13.7±6.3年。
- 61%的患者达到强化血糖控制,21.6%使用高风险药物达到强化控制。
- 高风险药物强化控制组较保守控制且低风险药物组的复合结局风险增加近50%(RR 1.49,95%CI 1.08-2.05)。
关键数值与推荐
- 强化血糖控制定义为HbA1c<53 mmol/mol(<7%)。
- 保守血糖控制定义为HbA1c 54-69 mmol/mol(7.1-8.5%)。
- 高风险药物包括胰岛素和磺脲类;低风险药物为其他降糖药。
- 复合结局为达到强化控制后30天内的急诊就诊、住院或死亡。
临床怎么用
- 对≥75岁糖尿病患者应重新评估个体化血糖目标,避免不必要的强化控制。
- 使用胰岛素或磺脲类时需警惕低血糖风险,尤其在强化控制设定下。
- 考虑对老年患者优先选择低血糖风险较低的降糖方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: More than 25% of older adults (age ≥75 years) have diabetes and may be at risk of adverse events related to treatment. The aim of this study was to assess the prevalence of intensive glycaemic control in this group, potential overtreatment among older adults and the impact of overtreatment on the risk of serious events. METHODS: We conducted a retrospective, population-based cohort study of community-dwelling older adults in Ontario using administrative data. Participants were ≥75 years of age with diagnosed diabetes treated with at least one anti-hyperglycaemic agent between 2014 and 2015. Individuals were categorised as having intensive or conservative glycaemic control (HbA1c <53 mmol/mol [<7%] or 54-69 mmol/mol [7.1-8.5%], respectively), and as undergoing treatment with high-risk (i.e. insulin, sulfonylureas) or low-risk (other) agents. We measured the composite risk of emergency department visits, hospitalisations, or death within 30 days of reaching intensive glycaemic control with high-risk agents. RESULTS: Among 108,620 older adults with diagnosed diabetes in Ontario, the mean (± SD) age was 80.6 (±4.5) years, 49.7% were female, and mean (± SD) diabetes duration was 13.7 (±6.3) years. Overall, 61% of individuals were treated to intensive glycaemic control and 21.6% were treated to intensive control using high-risk agents. Using inverse probability treatment weighting with propensity scores, intensive control with high-risk agents was associated with nearly 50% increased risk of the composite outcome compared with conservative glycaemic control with low-risk agents (RR 1.49, 95% CI 1.08, 2.05). CONCLUSIONS/INTERPRETATION: Our findings underscore the need to re-evaluate glycaemic targets in older adults and to reconsider the use of anti-hyperglycaemic medications that may lead to hypoglycaemia, especially in setting of intensive glycaemic control.
引用
- Lega IC, Campitelli MA, Austin PC, et al. Potential diabetes overtreatment and risk of adverse events among older adults in Ontario: a population-based study. Diabetologia. 2021. PMID: 33491105. doi:10.1007/s00125-020-05370-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。